{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:06:54Z","timestamp":1793506014168,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"DOI":"10.1007\/s11910-026-01498-y","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:53:07Z","timestamp":1780296787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping the Silent Onset of Parkinson\u2019s Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention"],"prefix":"10.1007","volume":"26","author":[{"given":"Valentina","family":"Leta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Ballanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-1939","authenticated-orcid":false,"given":"Roberto","family":"Cilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"12","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov disorders: official J Mov Disorder Soc. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"4","key":"1498_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mds.29317","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul S, Revesz T, Jaunmuktane Z, Warner TT, De Pablo-Fern\u00e1ndez E. Clinical Diagnostic Accuracy of Parkinson\u2019s Disease: Where Do We Stand? Movement disorders: official. J Mov Disorder Soc. 2023;38(4):558\u201366. https:\/\/doi.org\/10.1002\/mds.29317.","journal-title":"J Mov Disorder Soc"},{"issue":"2","key":"1498_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390. https:\/\/doi.org\/10.1016\/s1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204. https:\/\/doi.org\/10.1016\/s1474-4422(23)00404-0.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12149-020-01561-9","volume":"35","author":"HJ Son","year":"2021","unstructured":"Son HJ, Oh JS, Oh M, Lee SJ, Oh SJ, Chung SJ, et al. Test-retest reproducibility of dopamine transporter density measured with [(18)F]FP-CIT PET in patients with essential tremor and Parkinson\u2019s disease. Ann Nucl Med. 2021;35(3):299\u2013306. https:\/\/doi.org\/10.1007\/s12149-020-01561-9.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, Andersen KB, Knudsen K, Skj\u00e6rb\u00e6k C, Fedorova TD, Okkels N, et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077\u201388. https:\/\/doi.org\/10.1093\/brain\/awaa238.","journal-title":"Brain"},{"issue":"5","key":"1498_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41593-025-01910-9","volume":"28","author":"KB Andersen","year":"2025","unstructured":"Andersen KB, Krishnamurthy A, Just MK, Van Den Berge N, Skj\u00e6rb\u00e6k C, Horsager J, et al. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals. Nat Neurosci. 2025;28(5):925\u201336. https:\/\/doi.org\/10.1038\/s41593-025-01910-9.","journal-title":"Nat Neurosci"},{"key":"1498_CR8","doi-asserted-by":"publisher","unstructured":"Cilia R, Arnaldi D, Ballanger B, Ceravolo R, De Micco R, Del Sole A, et al. Neuroimaging and Pathology Biomarkers in Parkinson\u2019s Disease and Parkinsonism. Brain Sci. 2026;16(1). https:\/\/doi.org\/10.3390\/brainsci16010110.","DOI":"10.3390\/brainsci16010110"},{"issue":"6","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25103","volume":"82","author":"V Kaasinen","year":"2017","unstructured":"Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Ann Neurol. 2017;82(6):873\u201382. https:\/\/doi.org\/10.1002\/ana.25103.","journal-title":"Ann Neurol"},{"issue":"2","key":"1498_CR10","doi-asserted-by":"publisher","first-page":"e200599","DOI":"10.1212\/CPJ.0000000000200599","volume":"16","author":"M Pudis","year":"2026","unstructured":"Pudis M, Rodr\u00edguez-Bel L, Cort\u00e9s-Romera M, Su\u00e1rez-Pi\u00f1era M. Dopaminergic Pathway Imaging. Neurol Clin Pract. 2026;16(2):e200599. https:\/\/doi.org\/10.1212\/CPJ.0000000000200599.","journal-title":"Neurol Clin Pract"},{"issue":"Suppl 1","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"s27","DOI":"10.2967\/jnumed.121.263197","volume":"63","author":"ED Wallert","year":"2022","unstructured":"Wallert ED, van de Giessen E, Knol RJJ, Beudel M, de Bie RMA, Booij J. Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. J Nucl Med. 2022;63(Suppl 1):s27\u201332. https:\/\/doi.org\/10.2967\/jnumed.121.263197.","journal-title":"J Nucl Med"},{"issue":"8","key":"1498_CR12","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/mds.30255","volume":"40","author":"M Dhadamus","year":"2025","unstructured":"Dhadamus M, Delva A, Deckers W, Vandenberghe W, Van Laere K. Normal [(18)F]FE-PE2I PET in Patients with Persistent Diagnostic Uncertainty after Abnormal [(123)I]FP-CIT SPECT. Mov disorders: official J Mov Disorder Soc. 2025;40(8):1709\u201313. https:\/\/doi.org\/10.1002\/mds.30255.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"15","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/wnl.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88(15):1461\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000003810.","journal-title":"Neurology"},{"issue":"10","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/mds.27777","volume":"34","author":"EA Honkanen","year":"2019","unstructured":"Honkanen EA, Saari L, Orte K, Gardberg M, Noponen T, Joutsa J, et al. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson\u2019s disease. Mov disorders: official J Mov Disorder Soc. 2019;34(10):1562\u20136. https:\/\/doi.org\/10.1002\/mds.27777.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"Pt 8","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136(Pt 8):2419\u201331. https:\/\/doi.org\/10.1093\/brain\/awt192.","journal-title":"Brain"},{"issue":"1","key":"1498_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/mds.28785","volume":"37","author":"D Arnaldi","year":"2022","unstructured":"Arnaldi D, Mattioli P, Fam\u00e0 F, Girtler N, Brugnolo A, Pardini M, et al. Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy. Mov disorders: official J Mov Disorder Soc. 2022;37(1):52\u201361. https:\/\/doi.org\/10.1002\/mds.28785.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"3","key":"1498_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, H\u00f6gl B, Boeve BF, Manni R, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744\u201359. https:\/\/doi.org\/10.1093\/brain\/awz030.","journal-title":"Brain"},{"issue":"4","key":"1498_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ana.27158","volume":"97","author":"EG Brown","year":"2025","unstructured":"Brown EG, Chahine LM, Siderowf A, Gochanour C, Kurth R, Marshall MJ, et al. Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease. Ann Neurol. 2025;97(4):730\u201340. https:\/\/doi.org\/10.1002\/ana.27158.","journal-title":"Ann Neurol"},{"issue":"6","key":"1498_CR19","doi-asserted-by":"publisher","first-page":"e214037","DOI":"10.1212\/wnl.0000000000214037","volume":"105","author":"L Chahine","year":"2025","unstructured":"Chahine L, Rosso AL, Troidl I, Ganguli M, Newman AB, Lopresti BJ, et al. Features of Prodromal Parkinson Disease and Dopaminergic Neurotransmission in Community-Dwelling Older Adults. Neurology. 2025;105(6):e214037. https:\/\/doi.org\/10.1212\/wnl.0000000000214037.","journal-title":"Neurology"},{"issue":"10 Pt 2","key":"1498_CR20","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1016\/j.neubiorev.2013.09.008","volume":"37","author":"D Lindenbach","year":"2013","unstructured":"Lindenbach D, Bishop C. Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson\u2019s disease. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2737\u201350. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.09.008.","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"1498_CR21","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1093\/brain\/awab191","volume":"144","author":"E Biondetti","year":"2021","unstructured":"Biondetti E, Santin MD, Valabr\u00e8gue R, Mangone G, Gaurav R, Pyatigorskaya N, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson\u2019s disease. Brain. 2021;144(10):3114\u201325. https:\/\/doi.org\/10.1093\/brain\/awab191.","journal-title":"Brain"},{"issue":"8","key":"1498_CR22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3174\/ajnr.A5702","volume":"39","author":"N Pyatigorskaya","year":"2018","unstructured":"Pyatigorskaya N, Magnin B, Mongin M, Yahia-Cherif L, Valabregue R, Arnaldi D, et al. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease. AJNR Am J Neuroradiol. 2018;39(8):1460\u20137. https:\/\/doi.org\/10.3174\/ajnr.A5702.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"1498_CR23","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/brain\/awaa216","volume":"143","author":"E Biondetti","year":"2020","unstructured":"Biondetti E, Gaurav R, Yahia-Cherif L, Mangone G, Pyatigorskaya N, Valabr\u00e8gue R, et al. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson\u2019s disease. Brain. 2020;143(9):2757\u201370. https:\/\/doi.org\/10.1093\/brain\/awaa216.","journal-title":"Brain"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"103577","DOI":"10.1016\/j.nicl.2024.103577","volume":"41","author":"E Alushaj","year":"2024","unstructured":"Alushaj E, Handfield-Jones N, Kuurstra A, Morava A, Menon RS, Owen AM, et al. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson\u2019sdisease: A 3T and 7T MRI study. Neuroimage Clin. 2024;41:103577. https:\/\/doi.org\/10.1016\/j.nicl.2024.103577.","journal-title":"Neuroimage Clin"},{"issue":"7","key":"1498_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mds.27730","volume":"34","author":"N Bergsland","year":"2019","unstructured":"Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T. Jr. Ventral posterior substantia nigra iron increases over 3 years in Parkinson\u2019s disease. Mov disorders: official J Mov Disorder Soc. 2019;34(7):1006\u201313. https:\/\/doi.org\/10.1002\/mds.27730.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"key":"1498_CR26","doi-asserted-by":"publisher","first-page":"118255","DOI":"10.1016\/j.neuroimage.2021.118255","volume":"239","author":"M Brammerloh","year":"2021","unstructured":"Brammerloh M, Morawski M, Friedrich I, Reinert T, Lange C, Pelicon P, et al. Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry. NeuroImage. 2021;239:118255. https:\/\/doi.org\/10.1016\/j.neuroimage.2021.118255.","journal-title":"NeuroImage"},{"issue":"4","key":"1498_CR27","doi-asserted-by":"publisher","first-page":"e93814","DOI":"10.1371\/journal.pone.0093814","volume":"9","author":"ST Schwarz","year":"2014","unstructured":"Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The \u2018swallow tail\u2019 appearance of the healthy nigrosome - a new accurate test of Parkinson\u2019s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS ONE. 2014;9(4):e93814. https:\/\/doi.org\/10.1371\/journal.pone.0093814.","journal-title":"PLoS ONE"},{"issue":"6","key":"1498_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/mds.28988","volume":"37","author":"L Chougar","year":"2022","unstructured":"Chougar L, Arsovic E, Gaurav R, Biondetti E, Faucher A, Valabr\u00e8gue R, et al. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Mov disorders: official J Mov Disorder Soc. 2022;37(6):1245\u201355. https:\/\/doi.org\/10.1002\/mds.28988.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"5","key":"1498_CR29","doi-asserted-by":"publisher","first-page":"e213352","DOI":"10.1212\/wnl.0000000000213352","volume":"104","author":"G Palermo","year":"2025","unstructured":"Palermo G, Francesconi A, Bellini G, Morganti R, Migaleddu G, Di Carlo DT, et al. Involvement of the Nigrostriatal Pathway in Patients With Idiopathic Normal Pressure Hydrocephalus and Parkinsonism. Neurology. 2025;104(5):e213352. https:\/\/doi.org\/10.1212\/wnl.0000000000213352.","journal-title":"Neurology"},{"issue":"1","key":"1498_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.27223","volume":"98","author":"V Dzialas","year":"2025","unstructured":"Dzialas V, Bischof GN, M\u00f6llenhoff K, Drzezga A, van Eimeren T. Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson\u2019s Disease. Ann Neurol. 2025;98(1):120\u201335. https:\/\/doi.org\/10.1002\/ana.27223.","journal-title":"Ann Neurol"},{"issue":"9","key":"1498_CR31","doi-asserted-by":"publisher","first-page":"e213499","DOI":"10.1212\/wnl.0000000000213499","volume":"104","author":"V R\u00e4ty","year":"2025","unstructured":"R\u00e4ty V, Kuusim\u00e4ki T, Majuri J, Vahlberg T, Gardberg M, Noponen T, et al. Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years. Neurology. 2025;104(9):e213499. https:\/\/doi.org\/10.1212\/wnl.0000000000213499.","journal-title":"Neurology"},{"issue":"1","key":"1498_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-021-00250-2","volume":"7","author":"MJ Lee","year":"2021","unstructured":"Lee MJ, Pak K, Kim H-K, Nudelman KN, Kim JH, Kim YH, et al. Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease. NPJ Parkinson\u2019s disease. 2021;7(1):104. https:\/\/doi.org\/10.1038\/s41531-021-00250-2.","journal-title":"NPJ Parkinson\u2019s disease"},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphar.2020.00435","volume":"11","author":"E Paredes-Rodriguez","year":"2020","unstructured":"Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C. The Noradrenergic System in Parkinson\u2019s Disease. Front Pharmacol. 2020;11:435. https:\/\/doi.org\/10.3389\/fphar.2020.00435.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1498_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337\u201341. https:\/\/doi.org\/10.1001\/archneur.60.3.337.","journal-title":"Arch Neurol"},{"issue":"1","key":"1498_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318(1):121\u201334. https:\/\/doi.org\/10.1007\/s00441-004-0956-9.","journal-title":"Cell Tissue Res"},{"issue":"s2","key":"1498_CR36","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/jpd-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N. Brain-First versus Gut-First Parkinson\u2019s Disease: A Hypothesis. J Parkinson\u2019s disease. 2019;9(s2):S281\u201395. https:\/\/doi.org\/10.3233\/jpd-191721.","journal-title":"J Parkinson\u2019s disease"},{"key":"1498_CR37","doi-asserted-by":"publisher","unstructured":"Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proceedings of the National Academy of Sciences. 2007;104(34):13804-9. doi: https:\/\/doi.org\/10.1073\/pnas.0702753104","DOI":"10.1073\/pnas.0702753104"},{"key":"1498_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuint.2016.11.009","volume":"102","author":"Y Vermeiren","year":"2017","unstructured":"Vermeiren Y, De Deyn PP. Targeting the norepinephrinergic system in Parkinson\u2019s disease and related disorders: The locus coeruleus story. Neurochem Int. 2017;102:22\u201332. https:\/\/doi.org\/10.1016\/j.neuint.2016.11.009.","journal-title":"Neurochem Int"},{"issue":"11","key":"1498_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/01.wnr.0000227984.84927.a7","volume":"17","author":"M Sasaki","year":"2006","unstructured":"Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson\u2019s disease. NeuroReport. 2006;17(11):1215\u20138. https:\/\/doi.org\/10.1097\/01.wnr.0000227984.84927.a7.","journal-title":"NeuroReport"},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neuroimage.2017.09.042","volume":"163","author":"MJ Betts","year":"2017","unstructured":"Betts MJ, Cardenas-Blanco A, Kanowski M, Jessen F, D\u00fczel E. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. NeuroImage. 2017;163:150\u20139. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.09.042.","journal-title":"NeuroImage"},{"issue":"2","key":"1498_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jmri.28414","volume":"57","author":"N He","year":"2023","unstructured":"He N, Chen Y, LeWitt PA, Yan F, Haacke EM. Application of Neuromelanin MR Imaging in Parkinson Disease. J Magn Reson Imaging. 2023;57(2):337\u201352. https:\/\/doi.org\/10.1002\/jmri.28414.","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"1498_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/brain\/awad300","volume":"147","author":"P Trujillo","year":"2024","unstructured":"Trujillo P, Aumann MA, Claassen DO. Neuromelanin-sensitive MRI as a promising biomarker of catecholamine function. Brain. 2024;147(2):337\u201351. https:\/\/doi.org\/10.1093\/brain\/awad300.","journal-title":"Brain"},{"issue":"7","key":"1498_CR43","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/mds.26201","volume":"30","author":"G Castellanos","year":"2015","unstructured":"Castellanos G, Fern\u00e1ndez-Seara MA, Lorenzo-Betancor O, Ortega-Cubero S, Puigvert M, Uranga J, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson\u2019s disease. Mov disorders: official J Mov Disorder Soc. 2015;30(7):945\u201352. https:\/\/doi.org\/10.1002\/mds.26201.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"4","key":"1498_CR44","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/brain\/awad338","volume":"147","author":"C Laurencin","year":"2024","unstructured":"Laurencin C, Lancelot S, Brosse S, M\u00e9rida I, Redout\u00e9 J, Greusard E, et al. Noradrenergic alterations in Parkinson\u2019s disease: a combined 11\u00a0C-yohimbine PET\/neuromelanin MRI study. Brain. 2024;147(4):1377\u201388. https:\/\/doi.org\/10.1093\/brain\/awad338.","journal-title":"Brain"},{"key":"1498_CR45","doi-asserted-by":"publisher","first-page":"120588","DOI":"10.1016\/j.neuroimage.2024.120588","volume":"291","author":"P Liu","year":"2024","unstructured":"Liu P, Wang X, Zhang Y, Huang P, Jin Z, Cheng Z, et al. PENCIL imaging: A novel approach for neuromelanin sensitive MRI in Parkinson\u2019s disease. NeuroImage. 2024;291:120588. https:\/\/doi.org\/10.1016\/j.neuroimage.2024.120588.","journal-title":"NeuroImage"},{"issue":"2","key":"1498_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00702-023-02721-7","volume":"131","author":"G Palermo","year":"2024","unstructured":"Palermo G, Galgani A, Bellini G, Lombardo F, Martini N, Morganti R, et al. Neurogenic orthostatic hypotension in Parkinson\u2019s disease: is there a role for locus coeruleus magnetic resonance imaging? J Neural Transm (Vienna). 2024;131(2):157\u201364. https:\/\/doi.org\/10.1007\/s00702-023-02721-7.","journal-title":"J Neural Transm (Vienna)"},{"issue":"21","key":"1498_CR47","doi-asserted-by":"publisher","first-page":"R1051","DOI":"10.1016\/j.cub.2015.09.039","volume":"25","author":"LA Schwarz","year":"2015","unstructured":"Schwarz LA, Luo L. Organization of the locus coeruleus-norepinephrine system. Curr Biol. 2015;25(21):R1051\u20136. https:\/\/doi.org\/10.1016\/j.cub.2015.09.039.","journal-title":"Curr Biol"},{"issue":"7","key":"1498_CR48","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/ene.13628","volume":"25","author":"J Wang","year":"2018","unstructured":"Wang J, Li Y, Huang Z, Wan W, Zhang Y, Wang C, et al. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson\u2019s disease and its phenotypes. Eur J Neurol. 2018;25(7):949\u2013e73. https:\/\/doi.org\/10.1111\/ene.13628.","journal-title":"Eur J Neurol"},{"key":"1498_CR49","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.nicl.2022.103276","volume":"36","author":"B Xu","year":"2022","unstructured":"Xu B, He T, Lu Y, Jia J, Sahakian BJ, Robbins TW, et al. Locus coeruleus integrity correlates with inhibitory functions of the fronto-subthalamic \u2018hyperdirect\u2019 pathway in Parkinson\u2019s disease. Neuroimage Clin. 2022;36:103276. https:\/\/doi.org\/10.1016\/j.nicl.2022.103276.","journal-title":"Neuroimage Clin"},{"issue":"1\u20134","key":"1498_CR50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3109\/10799898709055001","volume":"7","author":"R Cash","year":"1987","unstructured":"Cash R, Raisman R, Cervera P, Javoy-Agid F, Agid Y. Pitfalls in membrane binding sites studies in post-mortem human brain. J Recept Res. 1987;7(1\u20134):527\u201354. https:\/\/doi.org\/10.3109\/10799898709055001.","journal-title":"J Recept Res"},{"issue":"3","key":"1498_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/cne.902870307","volume":"287","author":"V Chan-Palay","year":"1989","unstructured":"Chan-Palay V, Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J Comp Neurol. 1989;287(3):357\u201372. https:\/\/doi.org\/10.1002\/cne.902870307.","journal-title":"J Comp Neurol"},{"issue":"9","key":"1498_CR52","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/mds.28615","volume":"36","author":"B Huynh","year":"2021","unstructured":"Huynh B, Fu Y, Kirik D, Shine JM, Halliday GM. Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson\u2019s Disease. Mov disorders: official J Mov Disorder Soc. 2021;36(9):2085\u201393. https:\/\/doi.org\/10.1002\/mds.28615.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"1","key":"1498_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0047-6374(83)90100-8","volume":"23","author":"DM Mann","year":"1983","unstructured":"Mann DM. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev. 1983;23(1):73\u201394. https:\/\/doi.org\/10.1016\/0047-6374(83)90100-8.","journal-title":"Mech Ageing Dev"},{"issue":"7","key":"1498_CR54","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/jnnp-2011-301817","volume":"84","author":"K Del Tredici","year":"2013","unstructured":"Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson\u2019s disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84(7):774\u201383. https:\/\/doi.org\/10.1136\/jnnp-2011-301817.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1498_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnagi.2016.00196","volume":"8","author":"IU Isaias","year":"2016","unstructured":"Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, et al. Neuromelanin Imaging and Dopaminergic Loss in Parkinson\u2019s Disease. Front Aging Neurosci. 2016;8:196. https:\/\/doi.org\/10.3389\/fnagi.2016.00196.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1498_CR56","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/brain\/awx348","volume":"141","author":"M Sommerauer","year":"2018","unstructured":"Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, et al. Evaluation of the noradrenergic system in Parkinson\u2019s disease: an 11\u00a0C-MeNER PET and neuromelanin MRI study. Brain. 2018;141(2):496\u2013504. https:\/\/doi.org\/10.1093\/brain\/awx348.","journal-title":"Brain"},{"issue":"Pt 4","key":"1498_CR57","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/brain\/aww006","volume":"139","author":"M Ehrminger","year":"2016","unstructured":"Ehrminger M, Latimier A, Pyatigorskaya N, Garcia-Lorenzo D, Leu-Semenescu S, Vidailhet M, et al. The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2016;139(Pt 4):1180\u20138. https:\/\/doi.org\/10.1093\/brain\/aww006.","journal-title":"Brain"},{"issue":"1\u20132","key":"1498_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000350291","volume":"70","author":"K Matsuura","year":"2013","unstructured":"Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, et al. Neuromelanin magnetic resonance imaging in Parkinson\u2019s disease and multiple system atrophy. Eur Neurol. 2013;70(1\u20132):70\u20137. https:\/\/doi.org\/10.1159\/000350291.","journal-title":"Eur Neurol"},{"issue":"7","key":"1498_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","volume":"20","author":"C Ohtsuka","year":"2014","unstructured":"Ohtsuka C, Sasaki M, Konno K, Kato K, Takahashi J, Yamashita F, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord. 2014;20(7):755\u201360. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.04.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1498_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1148\/radiol.2016160662","volume":"283","author":"ST Schwarz","year":"2017","unstructured":"Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP. In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. Radiology. 2017;283(3):789\u201398. https:\/\/doi.org\/10.1148\/radiol.2016160662.","journal-title":"Radiology"},{"issue":"3","key":"1498_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.28945","volume":"37","author":"CF Madelung","year":"2022","unstructured":"Madelung CF, Meder D, Fuglsang SA, Marques MM, Boer VO, Madsen KH, et al. Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson\u2019s Disease. Mov disorders: official J Mov Disorder Soc. 2022;37(3):479\u201389. https:\/\/doi.org\/10.1002\/mds.28945.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"4","key":"1498_CR62","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2967\/jnumed.117.190975","volume":"59","author":"A Nahimi","year":"2018","unstructured":"Nahimi A, Sommerauer M, Kinnerup MB, \u00d8stergaard K, Winterdahl M, Jacobsen J, et al. Noradrenergic Deficits in Parkinson Disease Imaged with (11)C-MeNER. J Nucl Med. 2018;59(4):659\u201364. https:\/\/doi.org\/10.2967\/jnumed.117.190975.","journal-title":"J Nucl Med"},{"issue":"6","key":"1498_CR63","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mds.27411","volume":"33","author":"M Sommerauer","year":"2018","unstructured":"Sommerauer M, Hansen AK, Parbo P, Fedorova TD, Knudsen K, Frederiksen Y, et al. Decreased noradrenaline transporter density in the motor cortex of Parkinson\u2019s disease patients. Mov disorders: official J Mov Disorder Soc. 2018;33(6):1006\u201310. https:\/\/doi.org\/10.1002\/mds.27411.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"key":"1498_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.013","volume":"75","author":"KB Andersen","year":"2020","unstructured":"Andersen KB, Hansen AK, Sommerauer M, Fedorova TD, Knudsen K, Vang K, et al. Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder - A PET study. Parkinsonism Relat Disord. 2020;75:63\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.013.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1498_CR65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ana.410300308","volume":"30","author":"P Gaspar","year":"1991","unstructured":"Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson\u2019s disease. Ann Neurol. 1991;30(3):365\u201374. https:\/\/doi.org\/10.1002\/ana.410300308.","journal-title":"Ann Neurol"},{"issue":"9","key":"1498_CR66","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awab236","volume":"144","author":"CEJ Doppler","year":"2021","unstructured":"Doppler CEJ, Kinnerup MB, Brune C, Farrher E, Betts M, Fedorova TD, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson\u2019s disease. Brain. 2021;144(9):2732\u201344. https:\/\/doi.org\/10.1093\/brain\/awab236.","journal-title":"Brain"},{"key":"1498_CR67","doi-asserted-by":"publisher","unstructured":"Doppler CEJ, Smit JAM, Hommelsen M, Seger A, Horsager J, Kinnerup MB, et al. Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson\u2019s disease. Sleep. 2021;44(8). https:\/\/doi.org\/10.1093\/sleep\/zsab040.","DOI":"10.1093\/sleep\/zsab040"},{"key":"1498_CR68","doi-asserted-by":"publisher","first-page":"106048","DOI":"10.1016\/j.nbd.2023.106048","volume":"179","author":"JL McKay","year":"2023","unstructured":"McKay JL, Nye J, Goldstein FC, Sommerfeld B, Smith Y, Weinshenker D, et al. Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson\u2019s disease. Neurobiol Dis. 2023;179:106048. https:\/\/doi.org\/10.1016\/j.nbd.2023.106048.","journal-title":"Neurobiol Dis"},{"key":"1498_CR69","doi-asserted-by":"publisher","first-page":"105295","DOI":"10.1016\/j.nbd.2021.105295","volume":"152","author":"MB Kinnerup","year":"2021","unstructured":"Kinnerup MB, Sommerauer M, Damholdt MF, Schaldemose JL, Ismail R, Terkelsen AJ, et al. Preserved noradrenergic function in Parkinson\u2019s disease patients with rest tremor. Neurobiol Dis. 2021;152:105295. https:\/\/doi.org\/10.1016\/j.nbd.2021.105295.","journal-title":"Neurobiol Dis"},{"issue":"14","key":"1498_CR70","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/WNR.0b013e3282ef69f9","volume":"18","author":"IU Isaias","year":"2007","unstructured":"Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, et al. [123I]FP-CIT striatal binding in early Parkinson\u2019s disease patients with tremor vs. akinetic-rigid onset. NeuroReport. 2007;18(14):1499\u2013502. https:\/\/doi.org\/10.1097\/WNR.0b013e3282ef69f9.","journal-title":"NeuroReport"},{"key":"1498_CR71","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2377-11-88","volume":"11","author":"IU Isaias","year":"2011","unstructured":"Isaias IU, Marotta G, Pezzoli G, Sabri O, Schwarz J, Crenna P, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol. 2011;11:88. https:\/\/doi.org\/10.1186\/1471-2377-11-88.","journal-title":"BMC Neurol"},{"issue":"6","key":"1498_CR72","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41582-023-00802-5","volume":"19","author":"K Ray Chaudhuri","year":"2023","unstructured":"Ray Chaudhuri K, Leta V, Bannister K, Brooks DJ, Svenningsson P. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nat reviews Neurol. 2023;19(6):333\u201345. https:\/\/doi.org\/10.1038\/s41582-023-00802-5.","journal-title":"Nat reviews Neurol"},{"issue":"2","key":"1498_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211. https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"1498_CR74","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s1474-4422(19)30140-1","volume":"18","author":"H Wilson","year":"2019","unstructured":"Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T \u03b1-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019;18(8):748\u201359. https:\/\/doi.org\/10.1016\/s1474-4422(19)30140-1.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1498_CR75","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in Parkinson\u2019s disease: A meta-analysis of positron emission tomography studies. Ann Neurol. 2017;81(2):171\u201380. https:\/\/doi.org\/10.1002\/ana.24859.","journal-title":"Ann Neurol"},{"issue":"10","key":"1498_CR76","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00259-020-04683-4","volume":"47","author":"P Fazio","year":"2020","unstructured":"Fazio P, Ferreira D, Svenningsson P, Halldin C, Farde L, Westman E, et al. High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson\u2019s disease cohort. Eur J Nucl Med Mol Imaging. 2020;47(10):2407\u201316. https:\/\/doi.org\/10.1007\/s00259-020-04683-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1498_CR77","doi-asserted-by":"publisher","first-page":"fcaf308","DOI":"10.1093\/braincomms\/fcaf308","volume":"7","author":"W Li","year":"2025","unstructured":"Li W, Lao-Kaim NP, Li R, Mart\u00edn-Bastida A, Roussakis AA, Searle GE, et al. Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson\u2019s disease. Brain Commun. 2025;7(5):fcaf308. https:\/\/doi.org\/10.1093\/braincomms\/fcaf308.","journal-title":"Brain Commun"},{"key":"1498_CR78","doi-asserted-by":"publisher","unstructured":"Z\u00e1rate RV, Hidalgo S, Navarro N, Molina-Mateo D, Arancibia D, Rojo-Cort\u00e9s F, et al. An Early Disturbance in Serotonergic Neurotransmission Contributes to the Onset of Parkinsonian Phenotypes in Drosophila melanogaster. Cells. 2022;11(9). https:\/\/doi.org\/10.3390\/cells11091544.","DOI":"10.3390\/cells11091544"},{"issue":"1","key":"1498_CR79","doi-asserted-by":"publisher","first-page":"15069","DOI":"10.1038\/s41598-023-42135-9","volume":"13","author":"M Oh","year":"2023","unstructured":"Oh M, Oh SJ, Lee SJ, Oh JS, Chung SJ, Kim JS. Diagnostic accuracy of (18)F-FP-CIT PET for clinically uncertain Parkinsonian syndrome. Sci Rep. 2023;13(1):15069. https:\/\/doi.org\/10.1038\/s41598-023-42135-9.","journal-title":"Sci Rep"},{"issue":"11","key":"1498_CR80","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1093\/brain\/awae210","volume":"147","author":"M Passaretti","year":"2024","unstructured":"Passaretti M, Cilia R, Rinaldo S, Rossi Sebastiano D, Orunesu E, Devigili G, et al. Neurophysiological markers of motor compensatory mechanisms in early Parkinson\u2019s disease. Brain. 2024;147(11):3714\u201326. https:\/\/doi.org\/10.1093\/brain\/awae210.","journal-title":"Brain"},{"issue":"4","key":"1498_CR81","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/mds.25828","volume":"29","author":"R Cilia","year":"2014","unstructured":"Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced Parkinsonism. Mov disorders: official J Mov Disorder Soc. 2014;29(4):575\u20137. https:\/\/doi.org\/10.1002\/mds.25828.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"4","key":"1498_CR82","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00259-024-06989-z","volume":"52","author":"I Apostolova","year":"2025","unstructured":"Apostolova I, Hellwig S, Karimzadeh A, Klutmann S, Meyer PT, Buchert R. Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion. Eur J Nucl Med Mol Imaging. 2025;52(4):1549\u201355. https:\/\/doi.org\/10.1007\/s00259-024-06989-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1498_CR83","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/wnf.0000000000000359","volume":"42","author":"EA Honkanen","year":"2019","unstructured":"Honkanen EA, Kemppainen N, Noponen T, Sepp\u00e4nen M, Joutsa J, Kaasinen V. Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism. Clin Neuropharmacol. 2019;42(5):181\u20133. https:\/\/doi.org\/10.1097\/wnf.0000000000000359.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1498_CR84","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ana.26957","volume":"96","author":"EK Saarinen","year":"2024","unstructured":"Saarinen EK, Kuusim\u00e4ki T, Lindholm K, Niemi K, Honkanen EA, Noponen T, et al. Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease. Ann Neurol. 2024;96(2):262\u201375. https:\/\/doi.org\/10.1002\/ana.26957.","journal-title":"Ann Neurol"},{"issue":"23","key":"1498_CR85","doi-asserted-by":"publisher","first-page":"e2861","DOI":"10.1212\/wnl.0000000000012064","volume":"96","author":"M Todisco","year":"2021","unstructured":"Todisco M, Zangaglia R, Minafra B, Pisano P, Trifir\u00f2 G, Bossert I, et al. Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. Neurology. 2021;96(23):e2861\u201373. https:\/\/doi.org\/10.1212\/wnl.0000000000012064.","journal-title":"Neurology"},{"key":"1498_CR86","doi-asserted-by":"publisher","first-page":"105311","DOI":"10.1016\/j.neubiorev.2023.105311","volume":"152","author":"F Krohn","year":"2023","unstructured":"Krohn F, Lancini E, Ludwig M, Leiman M, Guruprasath G, Haag L, et al. Noradrenergic neuromodulation in ageing and disease. Neurosci Biobehavioral Reviews. 2023;152:105311. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105311.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"1498_CR87","doi-asserted-by":"publisher","first-page":"1030609","DOI":"10.3389\/fphar.2022.1030609","volume":"13","author":"AK Evans","year":"2022","unstructured":"Evans AK, Defensor E, Shamloo M. Selective Vulnerability of the Locus Coeruleus Noradrenergic System and its Role in Modulation of Neuroinflammation, Cognition, and Neurodegeneration. Front Pharmacol. 2022;13:1030609. https:\/\/doi.org\/10.3389\/fphar.2022.1030609.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1498_CR88","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0197-0186(02)00049-9","volume":"41","author":"DL Feinstein","year":"2002","unstructured":"Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002;41(5):357\u201365. https:\/\/doi.org\/10.1016\/s0197-0186(02)00049-9.","journal-title":"Neurochem Int"},{"issue":"5","key":"1498_CR89","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1124\/mol.62.5.1043","volume":"62","author":"JD Troadec","year":"2002","unstructured":"Troadec JD, Marien M, Mourlevat S, Debeir T, Ruberg M, Colpaert F, et al. Activation of the mitogen-activated protein kinase (ERK(1\/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol. 2002;62(5):1043\u201352. https:\/\/doi.org\/10.1124\/mol.62.5.1043.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1498_CR90","doi-asserted-by":"publisher","first-page":"e16101","DOI":"10.1111\/ene.16101","volume":"31","author":"K Staer","year":"2024","unstructured":"Staer K, Iranzo A, Terkelsen MH, Stokholm MG, Danielsen EH, \u00d8stergaard K, et al. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder. Eur J Neurol. 2024;31(1):e16101. https:\/\/doi.org\/10.1111\/ene.16101.","journal-title":"Eur J Neurol"},{"issue":"12","key":"1498_CR91","doi-asserted-by":"publisher","first-page":"e16503","DOI":"10.1111\/ene.16503","volume":"31","author":"MH Terkelsen","year":"2024","unstructured":"Terkelsen MH, Iranzo A, Serradell M, Baun AM, Stokholm MG, Danielsen EH, et al. Cholinergic dysfunction in isolated rapid eye movement sleep behaviour disorder links to impending phenoconversion. Eur J Neurol. 2024;31(12):e16503. https:\/\/doi.org\/10.1111\/ene.16503.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1498_CR92","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/brain\/awad391","volume":"147","author":"N Okkels","year":"2024","unstructured":"Okkels N, Horsager J, Fedorova TD, Knudsen K, Skj\u00e6rb\u00e6k C, Andersen KB, et al. Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies. Brain. 2024;147(1):255\u201366. https:\/\/doi.org\/10.1093\/brain\/awad391.","journal-title":"Brain"},{"key":"1498_CR93","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-026-07834-1","author":"D Arnaldi","year":"2026","unstructured":"Arnaldi D, Mattioli P, Orso B, Raffa S, Lanfranchi F, Massa F, et al. Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum. Eur J Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s00259-026-07834-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1498_CR94","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. JAMA Neurol. 2017;74(8):933\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0985.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1498_CR95","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/mds.28139","volume":"35","author":"A Siderowf","year":"2020","unstructured":"Siderowf A, Jennings D, Stern M, Seibyl J, Eberly S, Oakes D, et al. Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. Mov disorders: official J Mov Disorder Soc. 2020;35(9):1550\u20137. https:\/\/doi.org\/10.1002\/mds.28139.","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"1","key":"1498_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/brain\/awaa365","volume":"144","author":"D Arnaldi","year":"2021","unstructured":"Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain. 2021;144(1):278\u201387. https:\/\/doi.org\/10.1093\/brain\/awaa365.","journal-title":"Brain"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-026-01498-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:53:08Z","timestamp":1780296788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-026-01498-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s11910-026-01498-y","relation":{},"ISSN":["1534-6293"],"issn-type":[{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"VL has received speaking honoraria from Bial, EverPharma, AbbVie, Britannia, Stada, Zambon, Merz, and Chiesi; Advisory board fees from Bial; Travel grants to attend educational congresses from Bial and Symprove. BB has nothing to disclose. VK has received speaking honoraria from Bial, Lundbeck, AbbVie, Nordic Infucare; Advisory board fees from AbbVie, and Nordic Infucare; grants from Research Council of Finland and P\u00e4ivikki and Sakari Sohlberg Foundation. RC has received speaking honoraria from Bial Italia Srl, EverPharma, Zambon Italia, Zambon SAU; Advisory board fees from Bial; Research support from the Italian Ministry of Health; Support for educational courses from: Zambon; BIAL; AbbVie, EverPharma; Lusofarmaco; Chiesi; Boston Scientific; MedTronic; InsighTech; GE Healthcare. He is Editor-in-chief of the \u2018Sensory and Motor Neuroscience\u2019 section of Brain Sciences (MDPI) and Associate Editor of Parkinsonism and Related Disorders (Elsevier).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Disclosures"}}],"article-number":"29"}}